Key terms

About THTX

Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montréal, Canada.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest THTX news

Apr 15 9:06pm ET Theratechnologies Announces Virtual Annual Meeting Apr 08 4:36pm ET Theratechnologies announces data presentation of SORT1+ technology at AACR Apr 05 1:27pm ET Theratechnologies Welcomes Elina Tea to Board Apr 05 11:37am ET Theratechnologies Strengthens Board with New Appointment Apr 05 11:04am ET Theratechnologies appoints Elina Tea to board of directors Mar 22 5:27pm ET Theratechnologies Refocuses on Pioneering Ovarian Cancer Trial Mar 22 2:57pm ET Theratechnologies Welcomes New Board Member Mar 22 10:07am ET Theratechnologies Refocuses on Commercial Growth Mar 22 9:39am ET Theratechnologies to phase down preclinical oncology research activities Mar 21 9:07pm ET Theratechnologies Bolsters Board with New Director Mar 21 1:27pm ET Theratechnologies Escalates Ovarian Cancer Trial Dose Mar 21 8:07am ET Theratechnologies Trials Novel Ovarian Cancer Treatment Mar 21 7:38am ET Theratechnologies starts increased dose level in Phase 1 trial of sudocetaxel Feb 29 1:20pm ET Analysts Offer Insights on Healthcare Companies: Theratechnologies (THTX), MoonLake Immunotherapeutics (MLTX) and DENTSPLY SIRONA (XRAY) Feb 27 8:08am ET Theratechnologies Faces FDA Setback on Trogarzo Feb 27 7:32am ET Theratechnologies announces FDA RTF regarding sBLA for Trogarzo Feb 22 7:53am ET Theratechnologies price target lowered to $5 from $8 at Canaccord Feb 21 7:33am ET Theratechnologies reports Q4 revenue $23.45M, consensus $23.36M Feb 20 7:41am ET Theratechnologies announces publication in Frontiers in Immunology on TH1902 Feb 15 7:35am ET Theratechnologies completes enrollment of first six patients in Phase 1 trial Jan 24 7:01am ET Theratechnologies receives CRL from FDA for 58 formulation of tesamorelin sBLA Jan 23 7:33am ET Theratechnologies says FDA continuing to review sBLA for tesamorelin F8

THTX Financials

1-year income & revenue

Key terms

THTX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

THTX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms